Hepatitis C virus non-structural protein NS3 (NS3) (NS3)

Hepatitis C virus non-structural protein NS3 is a multifunctional enzyme essential for the replication and pathogenesis of the Hepatitis C virus (HCV) [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906261/; MDPI, https://www.mdpi.com/1999-4915/16/2/245]. It contains an N-terminal serine protease domain and a C-terminal RNA helicase/NTPase domain [Wikipedia, https://en.wikipedia.org/wiki/Hepatitis_C_virus_nonstructural_protein_3]. The protease domain, in complex with its cofactor NS4A, is responsible for the proteolytic processing of the HCV polyprotein into mature non-structural proteins, including NS4A, NS4B, NS5A, and NS5B [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236431/]. Additionally, the NS3/4A protease suppresses the host's innate immune response by cleaving key signaling adapter proteins such as MAVS and TRIF, thereby blocking interferon production [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906261/]. The helicase domain utilizes energy from ATP hydrolysis to unwind double-stranded RNA intermediates during viral genome replication [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906261/]. Due to its indispensable role in the viral life cycle, NS3 is a major therapeutic target for direct-acting antiviral (DAA) agents known as NS3/4A protease inhibitors [RxList, https://www.rxlist.com/hcv_ns34a_protease_inhibitors/drug-class.htm]. These drugs, such as glecaprevir and grazoprevir, effectively block viral replication and have significantly improved cure rates for chronic hepatitis C [RxList, https://www.rxlist.com/hcv_ns34a_protease_inhibitors/drug-class.htm]. However, the emergence of resistance-associated substitutions and the need for careful management in patients with advanced liver disease remain important clinical considerations [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360050/].

Other names

Non-structural protein 3NS3 proteinp-70NS3/4A (complex)HCV NS3 proteaseHCV NS3 helicase

NS3/4A protease inhibitors are direct-acting antivirals that bind to the active site of the NS3 serine protease domain, thereby inhibiting the cleavage of the viral polyprotein into functional non-structural proteins required for viral replication [RxList, https://www.rxlist.com/hcv_ns34a_protease_inhibitors/drug-class.htm; NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236431/].